Compare Amphastar Pharmaceuticals Inc (AMPH) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Union Pacific Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Union Pacific Corporation trades at $287.37 (market cap $170.37B). The key difference: Union Pacific Corporation is far larger — about 206.2× Amphastar Pharmaceuticals Inc's market cap, and Union Pacific Corporation pays a 1.92% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | UNP | |
|---|---|---|
Market Cap | $826.08M | $170.37B |
Sector | Health | Industrials |
52-Week High | $30.81 | $286.96 |
52-Week Low | $16.87 | $214.91 |
Enterprise Value | $1.22B | $200.84B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Union Pacific (UNP) trades at $286.96, up 0.67% today, with strong technical momentum indicated by bullish moving averages. The company maintains robust fundamentals with a 29.2% net income margin and consistent earnings beats in recent quarters. Key developments include the proposed $85 billion merger with Norfolk Southern, though regulatory scrutiny remains. Cash flow from operations remains healthy at $9.29 billion for 2025, supporting dividend payments and strategic initiatives.
Outlook remains positive with analyst consensus targeting $296.27, though risks include merger approval uncertainties and a class-action lawsuit. The stock's current valuation at 23.62 P/E reflects premium pricing, requiring sustained earnings growth to justify further upside. Near-term focus is on Q2 2026 earnings release scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
